News & Events about Atricure Inc.
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 25, 2023...
Wesbanco Bank Inc. purchased a new position in AtriCure, Inc. (NASDAQ:ATRC Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,525 shares of the medical device companys stock, ...
StockNews.com started coverage on shares of AtriCure (NASDAQ:ATRC Get Rating) in a report published on Thursday morning. The firm issued a hold rating on the medical device companys stock. A number of other research analysts have also recently commented on the stock. BTIG Research cut...
AtriCure, Inc. (NASDAQ:ATRC Get Rating) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 1,800,000 shares, a growth of 13.2% from the February 13th total of 1,590,000 shares. Based on an average daily volume of ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference...